When Nancy Whiteman, 61, founded her cannabis edibles company, Wana Brands, almost a decade ago in Boulder, Colorado, the legal industry was relatively diverse and dominated by local startups. It helped that Wall Street banks and institutional investors took a hands-off approach to cannabis, leery of getting involved with a drug that’s still banned by the federal government. “It was a pretty even playing field for everybody- men, women, anybody who was interested,” Whiteman says.
In the spring of 2017, students at the Vaughn Next Century Learning Center, a charter school surrounded by strip malls in Pacoima, a working-class area of Los Angeles boxed in by freeways northeast of downtown, were under siege.
When word came out that the federal government was interested in knowing our conclusions on CBD, it seems to have spurred a wave of action. Approximately 140 people are signed up to testify at a public hearing in Silver Spring, Maryland, where agency representatives will consider testimony on the use and implementation of the drug.
HB-243, better known as the CARE Act, has cleared the Alabama Senate Judiciary Committee and will now head to the full Senate just one month after Republican State Rep. and former Alabama Bureau of Investigation agent Mike Ball introduced the bill. Advancing out of committee represents a crucial step for the key medical cannabis legislation, bringing Alabama that much closer to a legal and regulated medical cannabis program.
This website offers education and information on cannabis and related products, and is restricted to adults aged and older, or valid medical cannabis patients. Please enter your birthdate.
Please disable your ad blocker to avoid issues using social plugins on Cannvas.Me. Thanks.